Abstract: It is claimed the invention of a composition and a device to be used in medical therapy as a containment matrix in conformational intra-tissue beta brachytherapy. The composition is made so as to form a gel which can be injected intra-tissue without toxicity in the organism, holding in suspension during injection the particulate of a beta-emitting brachytherapy composition, and forming after injection a solid deposit that immobilizes the radiotherapeutic composition in the injection bolus, to prevent migration of the radioactive product into the surrounding tissues. The composition is injected with an apparatus dedicated to percutaneous intra-tissue injection comprising a 7-degree robotic apparatus, an automatic injection device under pressure, a needles system to provide the therapeutic composition application in the tissue to be treated with minimal trauma.
Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.
Type:
Application
Filed:
July 26, 2019
Publication date:
December 19, 2019
Inventors:
DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
Abstract: A bone regeneration agent for regenerating a deficient or resorbed bone due to an inflammatory bone resorption disease, containing a niacin compound as an active ingredient.
Abstract: A topical composition for nociceptive and neuropathic pain relief comprises several of menthol, camphor, methyl sulfonyl methane, lidocaine, arnica montana, Harpagophytum tincture, Emu oil, maqui powder, turmeric oil and in some embodiments methyl salicylate or capsaicin with Cannabis sativa.
Abstract: A mimic of an anti-angiogenic peptide is combined with a self-assembling peptide hydrogel to provide improved treatment for pathological neovascularization management. Pathological neovascularization may cause or worsen intraocular posterior segment diseases, such as diabetic retinopathy (DR) and wet age-related macular degeneration (wet AMD). The attachment of a therapeutic anti-angiogenic motif to a fibrillizing peptide backbone that undergoes nanofibrous self-assembly into an injectable hydrogel was found beneficial for the treatment of aberrant neovascularization. The peptide persists for extended periods in a target site for prolonging the therapeutic timeframe. This injectable hydrogel therapy may unlock potential clinical routes for treating many neovascular diseases.
Type:
Application
Filed:
June 14, 2019
Publication date:
December 19, 2019
Applicant:
New Jersey Institute of Technology
Inventors:
Vivek A. Kumar, Peter Nguyen, Biplab Sarkar, Sruti Rachapudi, Patricia Iglesias-Montoro
Abstract: An objective of the present invention is to provide lymphatically-transported self-emulsifying formulations for enhancing membrane permeability of poorly membrane-permeable compounds in oral administration of the compounds. It was discovered that by applying lymphatically-transported self-emulsifying formulations containing a surfactant containing oleic acid as a moiety or oily component to poorly membrane-permeable compounds containing a cyclic peptide and having features (i) and (ii) below, the membrane permeability and absorbability of the compounds can be improved: (i) log D (pH 7.4) value of the compounds is 3.2 or greater; and (ii) Caco-2 Papp (cm/sec) value of the compounds is 1.8E-6 or less.
Abstract: Disclosed is a ?-cyclodextrin-based star-shaped polymer and a preparation method therefor, and an integrated unimolecular micelle system for diagnosis and treatment based on the star-shaped polymer and the use thereof. The polymer has a structure represented by the following formula (I): wherein x=4-15, y=3-20, and z=10-30.
Type:
Application
Filed:
December 14, 2016
Publication date:
December 19, 2019
Inventors:
Lijuan Zhang, Wenjing Lin, Na Yao, Xiaofang Zhang
Abstract: The present invention relates to a multi-domain vesicle comprising an immunostimulatory material, a production method of the multi-domain vesicle and an immunomodulatory composition comprising the multi-domain vesicle. According to one aspect of the present invention, the multi-domain vesicle comprises: at least two liposomes making contact and connected with each other, and a multi-domain vesicle outer wall surrounding the at least two liposomes.
Abstract: The present invention relates to a multi-domain vesicle comprising an immunosuppressive factor control material, a production method of the multi-domain vesicle and an immunomodulatory composition comprising the multi-domain vesicle. According to one aspect of the present invention, the multi-domain vesicle comprises: at least two liposomes making contact and connected with each other, and a multi-domain vesicle outer wall surrounding the at least two liposomes.
Abstract: An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.
Type:
Application
Filed:
July 26, 2019
Publication date:
December 19, 2019
Applicant:
University of Louisville Research Foundation, Inc.
Abstract: A liposome for delivery of nucleic acid is provided herein, comprising cationic lipid compound, a phospholipid and a PEGylated lipid, wherein the cationic lipid compound is in an amount from 50 wt % to 90 wt % and consist of a lipid compound and a cholesterol lipid compound. A nucleic acid liposome formulation comprising the said liposome and the nucleic acid encapsulated by the liposome and the method for preparing the same are provided therein. Increased amount of nucleic acid can be loaded into the nucleic acid liposome formulation as described therein. Thus, at the same dosage, intake of the cationic lipid compound is decreased, thereby decreasing toxicity.
Abstract: Quick water-dispersible pharmaceutical compositions of Flucytosine in powder or granule form are provided that allow for ease of preparation of measured-dose, liquid suspensions that are palatable and suitable for pediatric administration. The compositions can include Flucytosine as an active or combination with other anti-fungal agents, suspending agent, sweetener, flavoring agent and other additional excipients. The compositions in granular or powder form are efficiently dissolvable/dispersible in water and can be provided encapsulated within a two-piece dispensing hard capsule or a packet or pouch for easy release.
Abstract: Disclosed are methods for hydration of ST-246 particles comprising exposing said particles to moisture by conveying volumes of air containing moisture.
Type:
Application
Filed:
July 23, 2019
Publication date:
December 19, 2019
Applicant:
SIGA TECHNOLOGIES, INC.
Inventors:
Shanthakumar R. TYAVANAGIMATT, Matthew Reeves, N K Peter SAMUEL, Steven PRIEBE, Ying TAN, Dennis E. HRUBY
Abstract: Disclosed herein is a method for producing microparticles of an active ingredient via an in-line recirculating mixing system, wherein the in-line recirculating mixing system comprises a mixer and a conduit couple to the mixer. The method disclosed herein comprises the steps of: (a) forming a continuous phase of a medium in the in-line recirculating mixing system; (b) allowing the continuous phase of the medium of the step (a) to come into contact with a first mixture of the active ingredient, a polymer and a solvent at a site in the conduit, thereby forming a second mixture, in the conduit; and (c) allowing the second mixture of the step (b) to enter the mixer and circulate in the in-line recirculating mixing system until the microparticles of the active ingredient are formed.
Type:
Application
Filed:
January 23, 2018
Publication date:
December 19, 2019
Applicant:
Savior Lifetec Corporation
Inventors:
Amy LIU, Alex CHOU, Shih-Hsie PAN, Mannching Sherry KU
Abstract: The present invention relates generally to the field of immunogenic compositions containing volatile salts. In certain embodiments, compositions and methods disclosed herein relate to producing and using novel combinations to create frozen immunogenic agents bound to adjuvant having improved formulations and improved consistency of distribution of adjuvant for storage and subsequent delivery to a subject in need thereof.
Type:
Application
Filed:
June 21, 2019
Publication date:
December 19, 2019
Inventors:
Kimberly Hassett, Pradyot Nandi, John Carpenter, Theodore Randolph
Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
Type:
Application
Filed:
January 16, 2019
Publication date:
December 19, 2019
Inventors:
Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
Abstract: The presently-disclosed subject matter relates to compositions of dual layer encapsulated cells, dual layer encapsulated stem cells. The presently-disclosed subject matter further relates to methods for improving retention of cells in vivo at a site of injury.
Type:
Application
Filed:
June 18, 2019
Publication date:
December 19, 2019
Inventors:
Anuhya Gottipati, Irina Kalashnikova, Ahmed Abdel-Latif, Bradley J. Berron
Abstract: The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.
Type:
Application
Filed:
January 18, 2019
Publication date:
December 19, 2019
Inventors:
Robert K. Yang, Richard C. Fuisz, Garry L. Myers, Joseph M. Fuisz
Abstract: The present invention relates to a composition for preventing or treating stenosis, in which the composition includes brown algae extract, and more particularly to a composition for preventing or treating stenosis, in which the composition includes brown algae-derived polyphenol as an active ingredient, thereby providing excellent prevention or treatment effect on stenosis including tracheal stenosis, glottic stenosis, vascular stenosis, and the like.
Type:
Application
Filed:
November 20, 2017
Publication date:
December 19, 2019
Applicant:
PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
Abstract: An object of the present invention is to provide a curcumin-containing preparation that enables efficient curcumin ingestion. The object is achieved by a curcumin-containing preparation comprising amorphous curcumin and being substantially free of crystalline curcumin, wherein, in an infrared absorption spectrum with curve fitting by a Voigt function, a ratio (Cp/Ap) is 0.25 or less, the ratio (Cp/Ap) being a ratio of peak intensity Cp having the maximum in the range of 1508.00 to 1513.00 cm?1 to peak intensity Ap having the maximum in the range of 1513.50 to 1517.00 cm?1.
Abstract: In certain embodiments, the present invention provides a method of increasing liquid pH on airway surface of a tissue in a patient in need thereof comprising administering an effective amount of a therapeutic composition comprising tromethamine to the patient.
Type:
Application
Filed:
May 23, 2017
Publication date:
December 19, 2019
Applicant:
UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventors:
Joseph Zabner, Michael J. Welsh, David A. Stoltz, Mahmoud Abou Alaiwa
Abstract: This invention relates to solid oral dosage forms of 2R6R-hydroxynorketamine or prodrugs thereof having Formula Ib, including any pharmaceutically acceptable salt of the foregoing, for use in a therapeutic method for the treatment of a depressive disorder in a patient.
Type:
Application
Filed:
June 5, 2017
Publication date:
December 19, 2019
Applicant:
SMALL PHARMA LTD
Inventors:
Peter Rands, Marie Layzell, Zelah Joel, Alan Armstrong, Richard Myerson
Abstract: 5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of treating and/or reducing the occurrence of respiratory depression caused by an opioid in a human patient or patient population using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist (e.g., fenfluramine). Methods of stimulating one or more 5-HT4 receptors in the brain of a patient undergoing treatment with an opioid, wherein the patient is at risk of respiratory depression, by administering a 5-HT4 agonist (e.g., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.
Type:
Application
Filed:
June 5, 2019
Publication date:
December 19, 2019
Applicant:
ZOGENIX INTERNATIONAL LIMITED
Inventors:
Bradley S. Galer, Carl L. Faingold, Parthena Martin
Abstract: An active for use in the treatment or inhibition of an inflammatory disease associated with over-activation of Toll-like Receptor 4 (TLR4), Toll-like Receptor 2 (TLR2) and Myeloid differentiating protein 88 (Myd88) adaptor-like protein (Mal) while maintaining a subject's ability to respond normally to a pathogen, in which the active is an oleamide or an immunomodulatory analogue thereof.
Abstract: The present invention concerns the use of lufenuron for controlling sea lice in a fish population, which comprises feeding lufenuron to the fish population according to a specific regime as outlined in the specification and claims. The process is especially suited for the treatment of salmon and provides prolonged effective protection against sea lice at sea.
Type:
Application
Filed:
August 30, 2019
Publication date:
December 19, 2019
Inventors:
David Blaser, Jacques Bouvier, Martin Fink, John Gerard McHenery, Steve Nanchen
Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.
Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.
Type:
Application
Filed:
February 6, 2017
Publication date:
December 19, 2019
Inventors:
Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
Abstract: The present invention relates to the novel use of Medonium dihydrate (MDI) with natural antioxidants, such as lycopene, beta-carotene and lutein, for the prevention and treatment of cebrovascular ischemia and neurodegenerative diseases, such as Alzheimer's disease.
Abstract: The invention relates to a composition containing N-acetyldiaminobutyric acid, a salt or an ester of N-acetyldiaminobutyric acid for application in a method for the treatment of the human or animal body.
Abstract: The present invention relates to a high-performance process for obtaining extracts enriched in organosulphur compounds of type S-alkenyl-L-cysteine and S-alkyl-L-cysteine. Said compounds are obtained from plants of the Allium genus and in addition, they are free of sulphoxides. In addition, the use of organosulphur compounds of type S-alkenyl-L-cysteine and S-alkyl-L-cysteine as therapeutic or nutraceutical agents in the prevention and treatment of human and animal diseases that incur in chronic inflammation is described.
Type:
Application
Filed:
January 25, 2018
Publication date:
December 19, 2019
Inventors:
Elier PAZ ROJAS, Fe Isabel GARCIA MACEIRA, Luis Aristides TORRES SANCHEZ, Vanesa RAMIREZ GONZALEZ, Maria Eugenia GARCIA RUBIÑO, Isaac TUNEZ FIÑANA, Ana Isabel GIRALDO POLO, Begoña MarÍa ESCRIBANO DURÁN, Eduardo AGÜERA MORALES, Evelio LUQUE CARABOT
Abstract: The present invention relates to a novel synergistic combination of N-acetylcysteine (NAC), taurine, a non-thiol anti-oxidant, and magnesium which has been discovered to treat airway inflammation and airway excess mucus.
Abstract: Pharmaceutical or nutraceutical formulations are provided for treating inflammation in a subject in need thereof, as well as methods of treating inflammation in a subject in need thereof by administering one of the formulations. In some aspects, the pharmaceutical or nutraceutical formulation includes an effective amount of (i) palmitoylethanolamide or a derivative thereof, and (ii) one, two, three or more different small-molecule polyphenols or derivatives thereof to alleviate one or more causes or symptoms of the inflammation in the subject. In some aspects, the formulations include all three, e.g. the formulations includes (i) palmitoylethanolamide or a derivative thereof, (ii) quercetin or a derivative thereof, and (iii) curcumin or a derivative thereof. In some instances, the components (i)-(iii) discussed above are present at a mass ratio of about (i) 4 mg to 6 mg of palmitoylethanolamide or a derivative thereof to (ii) about 0.5 to 2.5 mg curcumin or a derivative thereof, and (iii) about 0.5 mg to 1.
Type:
Application
Filed:
June 14, 2019
Publication date:
December 19, 2019
Applicants:
The Texas A&M University System, Core Vibe Health, Inc.
Inventors:
SUSANNE U. MERTENS-TALCOTT, ARIELA BETSY THOMAS, VINICIUS DE PAULA VENANCIO, GEOFFREY R. PFEIFER, BLAKE M. EBERSOLE
Abstract: The present disclosure relates generally to peroxyformic acid forming compositions and methods for forming peroxyformic acid, preferably in situ, and peroxyformic acid formed by said compositions and methods for the purpose of treating an animal tissue and providing an antimicrobial function thereon. present disclosure in particular relates to a residue-free teat treatment composition for the treatment of an animal tissue, especially bovine teats, which provides antimicrobial efficacy and does not leave a non-food ingredient residue on treated teats.
Type:
Application
Filed:
June 14, 2019
Publication date:
December 19, 2019
Inventors:
Junzhong Li, Alex Thomas, Allison Prideaux, David D. McSherry, Joseph Morelli, Richard Staub
Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.
Type:
Application
Filed:
August 26, 2019
Publication date:
December 19, 2019
Inventors:
Susan Abdel-Rahman, Barry L. Preuett, J. Steven Leeder
Abstract: Genetic and epigenetic diseases and disorders are treated with FDA approved dietary compositions in the form of dietary supplements and nutraceuticals. The diseases and disorders to be treated include Rett syndrome, trinucleotide repeat diseases such as Fragile X syndrome, memory impairment, chronic inflammation, pre-cancerous conditions which involve cancer stem cells, and post-cancerous conditions which involve cancer stem cells which have survived in spite of cancer treatment. Treatment options include prophylactic treatment which is initiated prior to the development of the symptoms of the disease or disorder.
Abstract: Provided herein are methods of treating multiple sclerosis with dimethyl fumarate using an up-titration regimen. The methods provided herein are to reduce dimethyl fumarate-related gastro-intestinal adverse events in multiple sclerosis patients.
Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
Type:
Application
Filed:
August 29, 2019
Publication date:
December 19, 2019
Inventors:
Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
Abstract: A method of treating refractory or resistant pancreatic cancer by administering: (i) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel; or (ii) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel, and a therapeutically effective amount of gemcitabine.
Type:
Application
Filed:
January 4, 2018
Publication date:
December 19, 2019
Applicant:
SynCore Biotechnology Co., Ltd
Inventors:
Ruey-Kuen Hsieh, Hui-Yuan Tseng, Sih-Ting Lin
Abstract: The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
Abstract: Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.
Type:
Application
Filed:
February 6, 2018
Publication date:
December 19, 2019
Applicant:
United Kingdom Research and Innovation
Inventors:
Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria, Carlos Andre Passos Bastos
Abstract: The present invention provides methods and compositions for treating or preventing breast cancer with S-equol. The method and compositions are particularly suited to treating triple-negative breast cancer. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
Type:
Application
Filed:
April 15, 2019
Publication date:
December 19, 2019
Applicant:
The Board of Regents of the University of Texas System
Abstract: The present invention provides methods and compositions for treating or preventing melanoma with S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
Type:
Application
Filed:
April 15, 2019
Publication date:
December 19, 2019
Applicant:
The Board of Regents of the University of Texas System
Abstract: Methods of treating osteoporosis by administering synergistically effective amounts of genistein and a bisphosphonate, or pharmaceutically acceptable salts thereof.
Abstract: The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of hypertriglyceridemia, associated with chemotherapy and hyperglycemia.
Type:
Application
Filed:
June 14, 2019
Publication date:
December 19, 2019
Inventors:
Muhammed Majeed, Kalyanam Nagabhushanam